DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,767 filers reported holding DANAHER CORPORATION in Q4 2020. The put-call ratio across all filers is 0.97 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $702,867 | +20.1% | 2,833 | +16.2% | 0.05% | +30.0% |
| Q2 2023 | $585,120 | -10.8% | 2,438 | -6.3% | 0.04% | -18.4% |
| Q1 2023 | $656,135 | -19.6% | 2,603 | -15.4% | 0.05% | -25.8% |
| Q4 2022 | $816,511 | +10.8% | 3,076 | +7.8% | 0.07% | -7.0% |
| Q3 2022 | $737,000 | +9.5% | 2,854 | +7.5% | 0.07% | +12.7% |
| Q2 2022 | $673,000 | -8.3% | 2,656 | +6.1% | 0.06% | +12.5% |
| Q1 2022 | $734,000 | -8.6% | 2,503 | +2.5% | 0.06% | -5.1% |
| Q4 2021 | $803,000 | +9.4% | 2,441 | +1.2% | 0.06% | +1.7% |
| Q3 2021 | $734,000 | +14.5% | 2,412 | +2.4% | 0.06% | +11.5% |
| Q2 2021 | $641,000 | +60.2% | 2,355 | +32.7% | 0.05% | +40.5% |
| Q1 2021 | $400,000 | -17.7% | 1,775 | -18.9% | 0.04% | -27.5% |
| Q4 2020 | $486,000 | +21.8% | 2,189 | -24.0% | 0.05% | -32.9% |
| Q1 2020 | $399,000 | +75.8% | 2,881 | +95.1% | 0.08% | +105.4% |
| Q4 2019 | $227,000 | +10.2% | 1,477 | +3.8% | 0.04% | +12.1% |
| Q3 2019 | $206,000 | – | 1,423 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |